Scott D, Mijch A, Lucas C R, Marshall V, Thomson N, Atkins R
Fairfield Infectious Diseases Hospital, Melbourne, Australia.
Transplant Proc. 1987 Feb;19(1 Pt 3):2159-60.
Renal transplantation in HBsAg+ chronic carriers has a relative low risk of progressive liver disease, with mortality associated with liver disease at 7%. In contrast, HBsAg+ recipients who acquired their disease in the early posttransplant period had a mortality of 60%. HBeAg-positive patients who remain persistently positive are a subgroup with a poor prognosis and should not be offered a renal transplant.
乙肝表面抗原阳性慢性携带者接受肾移植后发生进展性肝病的风险相对较低,与肝病相关的死亡率为7%。相比之下,在移植后早期感染疾病的乙肝表面抗原阳性受者的死亡率为60%。持续呈HBeAg阳性的患者是预后较差的亚组,不应接受肾移植。